grants4od.fund (Grants for Orphan Drugs)

developing a drug, from university lab bench to patients, is a lengthy and costly process. orphan drugs make no exception. historically, funding came from public institutions and agencies, venture capital, corporate venture, business angels, family offices and individuals. more recently, another class of stakeholders emerged, with a different rationale: patients organizations, foundations, and charities which fund academic teams, clinical trials investigators, start-ups and later-stage companies through non-dilutive (sponsored research agreements, grants) and/or dilutive capital (equity). connecting, and advising, orphan drugs developers with small or large grant-making patients associations, at any development stage, is our business. globally.